Laura was already sixteen years old when her younger sister, Taylor, was born. She watched as her sister bloomed from a happy, healthy baby to a smart and talented three-year-old.
A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.
MIT Technology Review
Families of patients are starting advocacy groups, raising money for research, and founding biotech companies to advance cures for rare diseases.
Taylor's Tale co-founder Laura King Edwards talked with Moab's KCYN radio about why she's running in all 50 states for Taylor and the rare disease community.
Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today the exclusive worldwide license of a next generation gene therapy AAV capsid portfolio from University of North Carolina at Chapel Hill.